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Abstract
The COVID-19 pandemic has led to mortality and morbidity since December 2019. Many possible
treatment options have been advised till date. The role of ivermectin in the treatment of COVID19 disease remains controversial. The aim of our study was to evaluate the effect of ivermectin in
hospitalized patients with non-severe and severe COVID-19 disease. We conducted a retrospective
cohort study that compared outcomes in 2 groups of COVID-19 patients hospitalized at the largest
tertiary care center of Pakistan. The study group was given ivermectin along with standard
treatment of covid-19 disease; the comparison group was not. Data on mortality, inflammatory
markers such as C-reactive protein (CRP) and ferritin, length of hospital stay and baseline
characteristics were collected from Aga Khan University’s database from October 2020 till
February 2021. Statistical analysis was done to determine the effectiveness of ivermectin in nonsevere and severe COVID-19. Comparison of effectiveness o fivermectin in both genders was also
conducted. The cohort included 188 patients out of which 90 were treated with ivermectin.
Mortality and length of hospitalization was not found to be significantly different in the study
group compared with the control group (5.6% vs 5.1%; p=0.87 and 5 days vs 4 days; p=0.27).
Analysis of secondary outcomes did not yield statistically significant results, apart from ferritin
levels which were significantly less in patients treated with ivermectin (547.1 vs 756.7; p=0.03).
The ferritin and CRP levels in affected males were higher than in females on admission and
discharge. Our findings suggest ivermectin does not significantly affect all-cause mortality, length
of hospitalization and CRP levels in hospitalized COVID-19 patients. Large scale randomized
controlled trials (RCTs) are required to further evaluate the role of ivermectin in covid-19 disease.
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Introduction
The SARS-CoV-2 pandemic that we are currently going through, started in the city of Wuhan in
China towards the end of 2019. The pandemic since then has continued the affect the lives of the
people throughout the globe. A total of over 162 million people have been infected whereas over
3.3 million lives were claimed by COVID-19 as of 16 May, 2021.[1] In Pakistan alone 900,552
cases have been confirmed while over 20,000 people passed away due to COVID-19.[2]
Many medications have been proposed as probable treatment but the scientific evidence does not
seem to support the use of majority of them. This includes interferon, hydroxychloroquine,
chloroquine, conventional anti-virals, mono-clonal antibody, convalescent plasma therapy, and
antirheumatics like tocilizumab. [3-6] Treatment, is largely based on symptomatic management of
the patient and prevention of complications. Steroids and remdesivir have shown positive
outcomes such as decreased mortality or recovery time in patients with COVID-19. [7, 8]
Ivermectin seems to be a promising drug for COVID-19. Its ability to impede protein transport
into host nucleus via inhibition of importin (IMP) α/β receptor are behind its antiviral properties.
It can therefore inhibit the replication processes in various RNA and DNA viruses, e.g, influenza,
Zika virus, Dengue virus, Porcine circovirus and others. [9, 10] Another possible contributing
mechanism is allosteric modulation of the P2X4 receptor, which leads to the secretion of a
chemotactic – Chemokine ligand 5 (CCL-5).[11] Some studies suggest that ivermectin might have
immunosuppressive effects.[12] This is particularly important since it indicates mitigation of
inflammatory response during SARS by the drug. Indeed in-vitro models support the theory that
in SARS-CoV-2 a similar inhibitory effect leading to decreased replication will be seen.[13] This
has spurred clinicians to consider using ivermectin as treatment in COVID-19. Peru has even
restarted to prescribe ivermectin to their out-patients – even with arguably insufficient
evidence.[14] To the best of our knowledge, gender-based role of ivermectin in COVID-19 has
not been discussed in literature as yet. The aim of our study was to evaluate the effect of ivermectin
on non-severe and severe COVID-19 disease and to see gender based difference of its
effectiveness.

Materials and Methods
A retrospective cohort study was conducted on hospitalized patients with COVID-19 disease
confirmed by nasopharyngeal RT-PCR at the Aga Khan University Hospital (AKUH) located in
largest cosmopolitan city of Karachi, in Pakistan between Oct 2020 and Feb 2021. The study
protocol was approved by the Ethics Review Committee (ERC) of the AKUH.
AKUH is a tertiary care hospital in Karachi in the largest city of Pakistan. We have recruited nonsevere and severe hospitalized patients of COVID-19 disease during study period and divided them
in a study group; who received two doses of 12mg ivermectin 24 hours apart and control group;
who had not received ivermectin. Both groups had received other standard treatment according to
hospital protocol for management of COVID-19 disease. We have excluded critical COVID-19
patients and patients who were discharged from emergency department or those seen in outpatient
clinics.
The disease severity was classified according to the WHO classification into non-severe, severe
and critically ill patients. Severe COVID-19 was defined as patients having respiratory distress
with a respiratory rate of 30 breaths per minute or more and oxygen saturations below 90% on
room air whereas non-severe COVID-19 was defined as absence of signs of severe COVID19.[15]
Along with the analysis of effect of ivermectin on the study and comparison group, we also
analyzed the effect of ivermectin on both the genders to see if there is a gender difference of its
effectiveness or not, as this has not been seen and analyzed in literature previously.
Our primary outcome was to investigate the effect of ivermectin on all-cause mortality and length
of hospitalization in said patients while inflammatory marker levels (CRP and ferritin) at discharge
& differences in the two genders were considered as secondary outcomes.
The data was collected from AKU’s Health Information Management Services (HIMS) department
on a predesigned questionnaire. Data on age, disease severity (severe or non-severe),
comorbidities, requirement of oxygen post-discharge and exposure to steroids (dexamethasone or
prednisone) and/or remdesivir were noted.
Statistical analysis: All statistical analysis was done using the SPSS (Release 19.0, standard
version). A descriptive analysis was performed for demographic features presented as mean±SD
for quantitative variable like age, gender and comorbidities. Disease severity, inflammatory
markers and length of hospital stay were compared between both the groups using Mann-Whitney

U test & chi-square test where necessary. Odds ratios with 95% confidence interval were
computed. In all analyses, p-value <0.05 was considered statistically significant.
Results
A total of 188 subjects of non-severe and severe COVID-19 disease were included. Out of 188
patients, 90 patients were a part of the study group whereas the remaining 98 were in the control
group. The baseline characteristics of both groups are summarized in Table 1.
There was a male predominance in both groups (68.9% in study and 65.3% in control group).
There was no significant difference of age and other comorbidities in both groups.
Overall, 61.7% had severe disease and patients in study group had a slightly more severe disease
than the control group (65.6% vs 58.2%; p=0.37). Likewise, steroids and remdesivir were used
more in the study group (66.7% vs 48%)
There was no significant difference noted on CRP levels at discharge (20.4 mg/L (interquartile
range, 10.3-36 mg/L) in study group while 18.5 mg/L (interquartile range, 8.5-47.5 mg/L) in the
control group [p=0.96]. We noted an increase in ferritin as the treatment went on across both
groups, however the increase in the ivermectin exposed group was significantly less than that in
the control group. Median ferritin levels at discharge in the study group was 547.1 mg/L
(interquartile range, 247.5-868.1 mg/L) while 756.7 mg/L (interquartile range, 313.2-1370.6
mg/L) in the control group [p=0.03] Table 2.
There were 5 mortalities in each group (5.6% vs. 5.1%; p=0.87). Age [OR = 1.15 (95%CI, 1.06 to
1.25); p<0.001] and disease severity [OR=5.93 (95% CI 0.74-48.17; p=0.048) was found to be an
independent factor of mortality in both groups. Mortality in the two genders was not found to be
significantly different [odds ratio = 1.16 (95%CI, 0.25 to 7.17); p = 1]; Table 3.
The median length of stay of study group was 5 days (interquartile range, 3-6 days) whereas it was
4 days (interquartile range, 3-6 days) in the control group [p=0.27]; Table 2. Length of
hospitalization in females was found to be 4 days (interquartile range, 1-10 days) and in males 4
days (interquartile range, 1-18 days) as well [p=0.40] Table 3.
It was also seen that ferritin and CRP levels in affected males were higher than in females at both
admission and discharge. Analysis did reveal a significant difference in ferritin on admission
(p<0.001), ferritin on discharge (p<0.001) and CRP on admission (p=0.021) between the two
genders. The difference in CRP on discharge was insignificant (p=0.866). Table 3 and Figure 1.

No side effects of ivermectin were seen in the study group.
Discussion
The role of ivermectin in the treatment of COVID-19 still remains controversial with some studies
showing favorable results [16, 17] while others opposing its use[18]. Our study did not show any
statistically significant changes in outcomes like patient mortality, length of hospital stay and
differences in CRP levels.
Earlier a study by Caly et al. sparked interest in health professionals across the whole world
showing the antiviral properties of ivermectin.[13] This compelled researchers to conduct studies
exploring the potential of the drug. There was an influx of studies earlier that claimed ivermectin
as an effective option against the pathogen [16,17,19-23]. Concerns regarding power of these tests,
biases and designs have existed, demanding more solid evidence for the use of ivermectin in
COVID-19 - this study opposes that claim.
These findings are also corroborated by a randomized clinical trial which failed to find a decreased
time of resolution of symptoms in said patients against placebo.[18] As for some studies which
show a positive impact of ivermectin in the disease, many studies have limitations as summarized
by National Institutes of Health (NIH).[24]
We agree with Camprubi et al. [25] about the dosage of ivermectin which might be a vital factor.
However its toxicity is a plausible concern, even though studies has shown safety of ivermectin.
[26-28]. In the study by Caly et al. [13] the doses used are ten-fold greater than those approved by
FDA. This concern, along with noted variable results upon reviewing studies, trials and analyses
exploring the use of ivermectin in COVID-19, made the European Medicines Agency advised
against its use in COVID-19.[29] Similarly the COVID-19 Treatment Guidelines Panel at NIH
seems to be hesitant, and rightly so, to suggest ivermectin as a treatment option in the disease. In
fact recently, they released a statement putting forward concerns related to the quality of studies
and trials. [30]
A meta-analysis of 3 observational studies by Padhy et al. [31] showed that ivermectin, as an
adjunct to other prospective drugs, reduced mortality and resulted in clinical improvement.
Furthermore Okumuş et al. also found ivermectin to be beneficial as an add-on therapy. [32]
However, the use of other drugs can interfere with ivermectin metabolism. Antiretrovirals such as
lopinavir/ritonavir and darunavir/cobicistat which inhibit cytochrome P450 3A4 – metabolizes

ivermectin. Ritonavir and cobicistat also inhibit the P-glycoprotein which usually takes ivermectin
out of the CNS, thereby facilitating toxic doses. [33, 34]
Differences in inflammatory markers in the two genders were noted. Higher ferritin & CRP levels
in men compared to women might point to a worse prognosis in males. Similar results have been
noted in other studies. [35, 36] These two studies go on to propose that testosterone has an
immunosuppressive effect which leads to greater susceptibility. Indeed a reduction in testosterone
has been linked to greater susceptibility such as in men of old age. [37] A study from China in
2020 concluded that males are ‘at risk for worse outcomes and death’ independent of age. [38] A
study from Italy corroborates this notion by reporting an increased mortality rate in men. [39]
However the same study did also report a higher incidence in women, which is in contrast to studies
suggesting the opposite. [40] In a large US cohort where comorbids were matched, males were
observed to be at risk for worse outcomes. [40] Other possible explanations have been offered one of which is a higher ACE2 concentration in men. [41] Attitudes have also been shown to differ
amongst men & women. [42] Our study though does not provide evidence for a higher mortality
or longer stay in males as explained below. We do encourage researchers to look into these
differences.
Our study supports the hypothesis that increased age is related to higher mortality in COVID-19
patients as in other studies. [43]
Ferritin has been shown to be related to fatal outcomes in COVID-19 due to its involvement with
the cytokine storm.[44, 45] Our results show significantly less ferritin levels were observed in the
ivermectin arm, which would suggest ivermectin did positively affect in the therapy of SARSCoV-2. It might still be possible that the effect of ivermectin might not translate into improvement
in length of hospital stay. This could explain why the difference in inflammatory marker levels did
not seem to affect length of stay or mortality in the two genders as well. Literature on the effect of
ivermectin on these parameters is variable. [18, 46]
We recommend that high-powered randomized controlled trials to determine the role of ivermectin
in the treatment of SARS-CoV-2.
Limitations: Retrospective cohorts are prone to informational bias. Potential differences between
groups might not be detected due to smaller sample size. Other treatment for COVID-19 like the
use of steroids and remdesivir, was more pronounced in the study group. The dosage of ivermectin
across all subjects in the study was not standardized.

Conclusions
This study does not provide evidence for the use of ivermectin in the treatment of COVID-19 in
severe and non-severe hospitalized patients. Furthermore, there was no significant difference seen
in any gender with respect to effect of ivermectin. Large scale RCTs are required to evaluate the
role of ivermectin in the COVID-19 disease.
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Table 1. Characteristics of Study and Control group
Study group
Female
Male
(N=28)
(N=62)
Age (years)
Mean (SD)
Median [Min, Max]

Control group
Female
Male
(N=34)
(N=64)

Total
Female
(N=62)

Male
(N=126)

58.7 (13.2)

57.7 (12.8)

57.4 (15.3)

54.6 (14.9)

58.0 (14.3)

56.2 (14.0)

57.5 (31.0,
85.0)

58.5 (32.0,
91.0)

58.5 (25.0,
88.0)

54.5 (26.0,
96.0)

58.0 (25.0,
88.0)

56.0 (26.0,
96.0)

10.0
(35.7%)
1.00
(3.6%)
8.00
(28.6%)
0 (0%)

22.0
(35.5%)
8.00
(12.9%)
12.0
(19.4%)
1.00
(1.6%)
2.00
(3.2%)
1.00
(1.6%)
13.0
(21.0%)
3.00
(4.8%)

13.0
(38.2%)
4.00
(11.8%)
8.00
(23.5%)
0 (0%)

32.0
(50.0%)
4.00
(6.3%)
7.00
(10.9%)
1.00
(1.6%)
0 (0%)

23.0
(37.1%)
5.00
(8.1%)
16.0
(25.8%)
0 (0%)

54.0
(42.9%)
12.0
(9.5%)
19.0
(15.1%)
2.00
(1.6%)
2.00
(1.6%)
2.00
(1.6%)
27.0
(21.4%)
8.00
(6.3%)

1.00
(3.6%)
12.0
(42.9%)
15.0
(53.6%)

1.00
(1.6%)
16.0
(25.8%)
45.0
(72.6%)

11.0
(32.4%)
8.00
(23.5%)
15.0
(44.1%)

7.00
(10.9%)
25.0
(39.1%)
32.0
(50.0%)

12.0
(19.4%)
20.0
(32.3%)
30.0
(48.4%)

8.00
(6.3%)
41.0
(32.5%)
77.0
(61.1%)

10.0
(35.7%)
18.0
(64.3%)

21.0
(33.9%)
41.0
(66.1%)

15.0
(44.1%)
19.0
(55.9%)

26.0
(40.6%)
38.0
(59.4%)

25.0
(40.3%)
37.0
(59.7%)

47.0
(37.3%)
79.0
(62.7%)

27.0
47.0
29.0
58.0
(96.4%)
(75.8%)
(85.3%)
(90.6%)
Required
1.00
15.0
5.00
6.00
(3.6%)
(24.2%)
(14.7%)
(9.4%)
DM = Diabetes mellitus; HTN = Hypertension; IHD = Ischemic Heart Disease

56.0
(90.3%)
6.00
(9.7%)

105
(83.3%)
21.0
(16.7%)

Comorbids
None
DM
HTN
IHD
HTN/IHD
DM/IHD
DMIHTN
DM/HTN/IHD
Meds
Supportive Care
Steroids
Remdesivir And Steroids
Disease Severity
Non-severe
Severe
Oxygen Supplementation on
Discharge
Not Required

1.00
(3.6%)
1.00
(3.6%)
7.00
(25.0%)
0 (0%)

0 (0%)
0 (0%)
9.00
(26.5%)
0 (0%)

1.00
(1.6%)
14.0
(21.9%)
5.00
(7.8%)

1.00
(1.6%)
1.00
(1.6%)
16.0
(25.8%)
0 (0%)

Table 2. CRP, ferritin levels, length of hospitalization and outcome in both study and control group
Total
Study group;
Control group;
p-value
n=90
n=98
Ferritin on admission
465.2(233.8464.8(216.9465.6(256.10.58*
1009.7)
846.9)
1140.5)
Ferritin on discharge
640.9(271.1547.1(247.5756.7(313.20.03*
1160.6)
868.1)
1370.6)
CRP on admission
63.1(28.4-122.9)
67.6(35.5-130.5)
58.6(24-119.2)
0.21*

CRP on discharge

19(9.2-40)

20.4(10.3-36)

18.5(8.5-47.5)

0.96*

Length of hospital stay

4(3-6)

5(3-6)

4(3-6)

0.27*

Outcome
Discharged
Mortality

179(94.7)
10(5.3)

85(94.4)
5(5.6)

94(94.9)
5(5.1)

0.87

*Mann-Whitney U test

Table 3. Gender base difference on CRP, ferritin level, length of hospitalization and outcome in both
study and control group

CRP on Admission
(mg/L)
Mean (SD)
Median [Min, Max]
CRP on Discharge
(mg/L)
Mean (SD)
Median [Min, Max]
Ferritin on Admission
(mg/L)
Mean (SD)
Median [Min, Max]
Ferritin on Discharge
(mg/L)
Mean (SD)
Median [Min, Max]
Length of
Hospitalization (days)
Mean (SD)
Median [Min, Max]
Outcome
Discharged
Expired

Study group
Female
Male

Control group
Female
Male

Female

Male

(N=28)

(N=62)

(N=34)

(N=64)

(N=62)

(N=126)

74.9 (57.8)
61.2 [3.58,
249]

86.2 (59.5)
76.4 [5.06,
200]

58.2 (65.8)
40.4 [0.400,
306]

84.9 (63.6)
75.4 [0.26,
264]

66.0 (62.2)
48.0 [0.400,
306]

85.5 (61.4)
75.9 [0.260,
264]

0.021

29.0 (24.4)
23.3 [1.16,
88.1]

26.9 (30.0)
20.4 [0.300,
187]

26.8 (30.0)
18.7 [0.140,
122]

35.5 (40.4)
18.0 [0.450,
166]

27.7 (27.5)
19.2 [0.140,
122]

31.1 (35.6)
18.8 [0.300,
187]

0.866

589 (686)
401 [44.6,
3380]

753 (845)
530 [49.1,
5090]

426 (540)
262 [3.10,
2590]

880 (648)
615 [28.6,
2970]

502 (612)
301 [3.10, 3380]

815 (755)
555 [28.6,
5090]

571 (677)
435 [65.1,
3270]

749 (671)
597 [30.3,
3630]

460 (469)
271 [29.6,
1720]

1050 (649)
1040 [140,
2930]

523 (591)
304 [29.6,
3270]

879 (675)
708 [30.3,
3630]

<0.001

4.89 (2.08)
4.50 [2.00,
10.0]

4.85 (2.99)
5.00 [1.00,
18.0]

3.88 (1.65)
4.00 [1.00, 8.00]

4.83 (2.56)
4.00 [1.00,
15.0]

4.34 (1.91)
4.00 [1.00, 10.0]

4.84 (2.77)
4.00 [1.00,
18.0]

0.40

26.0 (92.9%)

59.0 (95.2%)

33.0 (97.1%)

59.0 (95.2%)

119 (94.4%)

1.00

2.00 (7.1%)

3.00 (4.8%)

1.00 (2.9%)

60.0
(93.8%)
4.00
(6.3%)

3.00 (4.8%)

7.0 (5.6%)

CRP – C Reactive Protein; SD – Standard deviation

Total
pvalue[
OR]

<0.001

Figure 1: Gender base difference of Serum Ferritin and CRP levels on admission

